Supplementary treatment with radiation and cytostatic ... No writing assistance was utilized in the production of this manuscript. Myasthenia gravis (MG) should be subgrouped into early-onset ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Treatments for myasthenia gravis include medications to help control and prevent symptoms related to muscle weakness and therapies during a myasthenic crisis (when symptoms worsen). Surgical ...

1 (PRNewsfoto/Johnson & Johnson) "We welcome the FDA's decision to grant Priority Review for the treatment of generalized myasthenia gravis, which underscores the need for additional treatment ...

In its fourth-quarter results update, Sanofi said it had discontinued the phase 3 URSA trial of tolebrutinib in patients with moderate-to-severe myasthenia gravis, but stressed the decision was ...

The Ministry of Food and Drug Safety announced on the 20th that it has approved the severe myasthenia gravis treatment "Vyvgart" (active ingredient efgartigimod alpha) from Belgian pharmaceutical ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Myasthenia gravis (MG) should be classified according ... and severity. With optimal treatment, the prognosis is good in terms of daily functions, quality of life and survival.